Like opposite poles of a magnet, great companies tend to attract each another.
Today Verici Dx (VRCI announced a strategic collaboration with Illumina in order to enhance the data mining & AI capability of its deep immuno-response, RNA signature & broader medical biobank of knowledge. With the aim of improving the predictive & diagnostic efficacy of its world beating kidney/donor transplant tests.
To me, this is a significant endorsement of the quality of both company’s technology. Particularly given considerable time, effort and management resource will be allocated to the work, which can be later showcased across the wider healthcare community.
What’s more, the agreement represents another major milestone in commercialising Verici Dx’s unique IPR - & will also enable the firm to stay at the forefront of improving patient outcomes.
CEO Sara Barrington adding: “Our leading-edge science depends on the ability to process vast amounts of data, and we believe there is no better tool to support us in this than Illumina’s Connected Analytics platform.
This represents a key step in the readiness of the near-term launches of our flagship Clarava & Tuteva products, as well as the long-term strategy for building the computational data analytics tools that will power the future of Verici Dx’s data science.”